
Novavax’s COVID-19 Vaccine Has an Edge Over Rivals, Says 5-Star Analyst
The coronavirus isn’t going away just yet. The number of cases in the US passed 4.5 million, bringing the total number of US deaths to 158K.The need for a vaccine could not be more profound. While the data is alarming, the good news is that with each passing day, a vaccine solution is closer to becoming a reality. There are several candidates in the race hoping to be first to market. B.Riley FBR analyst Mayank Mamtani believes Novavax’s (NVAX) vaccine candidate, NVX-CoV2373, could make its way from the back of the pack to the front.Mamtani said, “While acknowledging the 6-8 …read more […]